Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

by divibasicbldev | Mar 2, 2023 | Press Releases

– Prof. Steinman’s groundbreaking research linking Epstein-Barr virus to multiple sclerosis named a runner-up for the 2022 Science Magazine Breakthrough of the Year -PALO ALTO, Calif. and MIAMI, Fla., March 02, 2023 (GLOBE NEWSWIRE) — Pasithea...

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

by divibasicbldev | Feb 23, 2023 | Press Releases

Event theme, “MS: Going Viral” touches on the role of viruses in MS, particularly Epstein-Barr, a topic related to Company’s PAS-002 drug discovery programPALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp....

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

by divibasicbldev | Feb 16, 2023 | Press Releases

Prestigious award presented by Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping FoundationPALO ALTO, Calif. and MIAMI, Fla., Feb. 16, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

by divibasicbldev | Jan 18, 2023 | Press Releases

— Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023 — MIAMI BEACH, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...

Majority of Stockholders Support Pasithea Directors at Special Meeting

by divibasicbldev | Dec 14, 2022 | Press Releases

MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central...

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

by divibasicbldev | Dec 12, 2022 | Press Releases

MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central...